What is the recommended dosage of Keflex (Cephalexin) for treating cellulitis in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Keflex (Cephalexin) Dosage for Adult Cellulitis

For adults with non-purulent cellulitis, cephalexin 500 mg orally every 6 hours (four times daily) for 5-10 days is the recommended regimen, with 5 days being sufficient for uncomplicated cases that show clinical improvement. 1, 2

Standard Dosing Regimen

  • Cephalexin 500 mg orally every 6 hours is the IDSA-recommended dose for typical non-purulent cellulitis 1, 3
  • The FDA-approved adult dosage range is 1-4 grams daily in divided doses, with 500 mg every 12 hours specifically indicated for skin and skin structure infections 2
  • Treatment duration should be 5 days if clinical improvement occurs, as this is equally effective as 10 days for uncomplicated cellulitis 1
  • Extend therapy beyond 5 days only if the infection has not improved within this timeframe 1, 2

When Cephalexin is Appropriate

Cephalexin is the oral agent of choice for cellulitis caused by methicillin-susceptible Staphylococcus aureus and streptococci 1

  • Use for non-purulent cellulitis (no purulent drainage, exudate, or abscess) where β-hemolytic streptococci are the primary concern 3, 1
  • MRSA is an unusual cause of typical cellulitis—β-lactam monotherapy with cephalexin is appropriate in the absence of abscess, ulcer, or purulent drainage 1
  • Suitable for outpatient management in patients without systemic signs of infection 1

When to Modify or Avoid Cephalexin

Do not use cephalexin alone if any of these MRSA risk factors are present: 1

  • Purulent drainage or exudate (even without drainable abscess)
  • Penetrating trauma
  • Evidence of MRSA infection elsewhere on the body
  • Nasal colonization with MRSA
  • Injection drug use
  • Associated abscess or ulcer

For these situations, add MRSA coverage with clindamycin, TMP-SMX, doxycycline, or linezolid 3, 4

Higher Dose Considerations

  • For more severe infections or less susceptible organisms, larger doses may be needed 2
  • A 2023 pilot trial showed high-dose cephalexin (1000 mg four times daily) had fewer treatment failures (3.2%) compared to standard dose 500 mg (12.9%), though with more minor adverse effects 5
  • If daily doses exceeding 4 grams are required, consider parenteral cephalosporins 2

Special Populations and Situations

  • Penicillin-allergic patients (except immediate hypersensitivity): cephalexin remains an option 1
  • Renal impairment: reduce dosage proportionally when creatinine clearance is <30 mL/min 6
  • Morbidly obese patients: standard dosing appears adequate; empiric dose adjustment based solely on BMI may not be necessary 7

Essential Adjunctive Measures

  • Elevate the affected extremity to reduce edema 1
  • Treat predisposing conditions: tinea pedis (toe web infections), venous insufficiency, lymphedema, eczema 3, 1
  • Examine interdigital toe spaces in lower-extremity cellulitis—treating fissuring or maceration reduces recurrence 1

When to Escalate Care

Consider hospitalization or IV therapy if: 1

  • Concern for deeper infection (necrotizing fasciitis, abscess)
  • Poor adherence to oral therapy anticipated
  • Immunocompromised state
  • Outpatient treatment failing after 48-72 hours
  • Systemic toxicity present

For hospitalized patients with complicated cellulitis, IV cefazolin 0.5-1 gram every 8 hours is appropriate for non-MRSA infections 3

Common Pitfalls to Avoid

  • Don't extend treatment unnecessarily—5 days is adequate if clinical improvement has occurred 1
  • Don't automatically add MRSA coverage for typical non-purulent cellulitis without specific risk factors 1
  • Don't overlook underlying conditions (venous insufficiency, lymphedema, tinea pedis) that predispose to recurrent cellulitis 1
  • Don't ignore treatment failure—if no improvement by day 3-5, consider MRSA coverage or alternative diagnosis 3, 1

References

Guideline

Cephalexin Dosing and Management for Cellulitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clindamycin Dosage for Cellulitis Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The pharmacology of cephalexin.

Postgraduate medical journal, 1983

Research

Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis.

Journal of clinical pharmacy and therapeutics, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.